1Diaz R S, Sabino E C, Mayer A, et al. Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group[J].J Virol, 1995, 69: 3273-3281.
2Kampinga G A, Simonon A, van de Perre P, et al. Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C[J]. Virology, 1997, 227:63-76.
3Kim J H, McLinden R J, Mosca J D, et al. Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones[J]. J Acquir Immune Defic Syndr Hum Retrovirol,1996; 12:329-42.
4Otten R A, Ellenberger D L, Adams D R, et al. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina(pigtailed macaque) model[J]. J Infect Dis, 1999; 180
5Andersson S, Norrgren H, Dias F, et al. Molecular characterization of human mmunodeficiency virus (HIV)-I and -2in individuals from Guinea-Bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa[J].Vi
6Dern K, Rubsamen-Waigmann H, Unger R, Inhibition of HIV type 1replication by simultaneous infection of peripheral blood lymphocytes with human immunodeficiancy virus types 1 and 2[J]. AIDS Res Hum Retroviruses, 2001; 17:295-309.
7Dorrell L, Willcox B E, Jones E Y, et al. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53[J]. EurJ Immunol, 2001; 31:1747-1756.
8Peeters M. Recombinant HIV Sequences: Their Role in the Global Epidemic[A]. Korber B T, Brander C, Walker B D, et al. Molecular immunology compendium reviews[C]. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics,2000,
9#Jason T B, Daniel E C, Kenneth H M. Human Immunodeficiency Virus Superinfection and Recombination: Current State of Knowledge and Potential Clinical Consequences[J], Clinical Infectious diseases, 2002,34:1108-1114.
10Gao F, Robertson D L, Carruthers C D, et al. A comprehensive panel of near full length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1[J]. J Virol, 1998,72: 5680-5698.
6Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926
7Shibayama T, Masuda G, Ajisawa A, Hiruma K, Tsuda F, Nishizawa T, Takahashi M, Okamoto H. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. J Med Virol 2005; 76: 24-32
8Oronsaye FE, Oronsaye JI. Prevalence of HIV-positives and hepatitis B surface antigen-positives among donors in the University of Benin Teaching Hospital, Nigeria. Trop Doct 2004; 34: 159-160
9Sud A, Singh J, Dhiman RK, Wanchu A, Singh S, Chawla Y. Hepatitis B virus co-infection in HIV infected patients. Trop Gastroenterol 2001; 22: 90-92
10Heng BH, Goh KT, Chan R, Chew SK, Doraisingham S, Quek GH. Prevalence of hepatitis B virus (HBV) infection in Singapore men with sexually transmitted diseases and HIV infection: role of sexual transmission in a city state with intermediate HBV endemicity. J Epidemiol Community Health 1995; 49: 309-313
